|
Animal Studies
The first scientific evidence of a link between a drug for severe acne and depression was unveiled by Bath University in September 2006, following years of denials by the manufacturer that the prescription medicine could be in any way responsible for suicides.
The research showed that the drug, which had been given to British teenagers for more than two decades, causes depression in mice.
Biochemist Dr Sarah Bailey looked at how healthy mice were affected by a six-week course of Roaccutane, which has a similar structure to vitamin A.
She found that when given levels of Roaccutane equivalent to those used to treat teenagers, the creatures developed symptoms of depression, stress or despair. For more information, please click here to download the study in .pdf format .
Other work funded by Mr Grant focused on the the effects of a therapeutic
dose of Accutane on the adult brains of mice. It was suggested that
if Accutane caused depression then Accutane would influence the "embryonic-like"
regions of the adult brain. "Embryonic-like" regions of the adult
brain refer to regions where the birth of new neurons continues throughout
life.
Accutane was found to inhibit the growth of neurons in a brain area
called the hippocampus that is involved in memory and emotion. This
brain area was previously found to be smaller in patients with depression.
The report by Crandal et al, published in 2004 concluded that "This
report demonstrates that a clinical dose (1 mg/kg/day) of 13-cis-RA
in mice significantly reduces cell proliferation in the hippocampus
and the subventricular zone, suppresses hippocampal neurogenesis,
and severely disrupts capacity to learn a spatial radial maze task.
The results demonstrate that the regions of the adult brain where
cell proliferation is ongoing are highly sensitive to disruption by
a clinical dose of 13-cis-RA." This article can be downloaded
from http://www.pnas.org/cgi/content/full/101/14/5111.
|
Although the effects of Accutane/Roaccutane
on the devoloping brain of the fetus has been known since the drug
was introduced in 1982, there was no research conducted to examine
the effects of Accutane/Roaccutane on the adolescent or adult brain.
The emergence of cases of depression and suicide along with
spontanous reports which were consistently submitted to health authorties
(see ADR) did not prompt the FDA, NIH or Roche to conduct any meaningful
studies. At the FDA hearings in 2000, Roche representatives presented
a review of the literature and concluded that "although the role
of retinoic acid in the devoloping CNS is well characterized, extrapolation
to effects on the mature brain seem unwarranted" and were also
quoted in a newspaper article in 2003 saying "We've spent the
better part of 2 1/2 years trying to figure out how to conduct such
a study, and it has baffled the best scientific minds at both the
FDA and Roche -We are committed to finding out if there is any possible
link, but we haven't figured out how to do that" [Source, Did
A Powerful Acne Drug Play A Role In A Palo Alto 14-Year-Old's Killing
Himself? San Francisco Chronicle, April 2003]
Human Studies
In 1999, Mr Grant, whose own son committed suicide on Accutane, donated
money to animal and human studies to examine the effects of Accutane
on the adult human brain. Dr. Bremner, who looked at the effects of
accutane on brain function using brain imaging presented his findings
in November 2004. The study was subsequently published in the American
Journal of Psychiatry in 2005. The full study can be downloaded here
[Bremner 2005]. Briefly,
Dr Bremner compared the effect of Accutane on brain function and compared
the results to his published findings of the effects of depression
on brain function. Brain function was measured before and after four
months of treatment with Accutane (13 patients) and antibiotic (15
patients) using PET scans. Isotretinoin (but not antibiotic) treatment
was associated with decreased brain metabolism in the orbitofrontal
cortex, a brain area known to mediate symptoms of depression. This
study suggests that “isotretinoin treatment is associated with changes
in brain function”. The study also proved that Accutane must enter
the brain and therefore can cause depression, even if it is an acne
drug!
|
| For full list of articles on retinoids and the central nervous system click here |
Many scientific studies refer to Accutane or
Roaccutane as Isotretinoin or 13-cis-retinoic acid. The reason for this
is that the active ingredient of Accutane/Roaccutane is Isotretinoin
(which is the generic name for the drug) and Isotretinoin is chemically
known as 13-cis-retinoic acid.
Isotretinoin is sold under many brand names, including Accutane inside
the USA and as Roaccutane outside of the USA, both of these brands being
produced by Hoffmann-La Roche. It is also marketed as Accure (Alphapharm),
Oratane (Douglas Pharmaceuticals), Isohexal (Hexal Australia), Amnesteem
(Bertek) and Claravis (Barr).
Accutane/Roaccutane is in the class of compounds called retinoids that includes
the active form of Vitamin A.
The active ingredient of Accutane/Roaccutane is Isotretinoin, chemically
known as 13-cis-retinoic acid which is related to both retinoic acid
(cis-13-retinoic acid is an isomer of all-trans-retinoic acid) and retinol
(Vitamin A).
Retinoids are a family of natural and synthetic compounds related to
Vitamin A.
The majority of the functions of Vitamin A (growth, vision, reproduction,
immune response, nervous system devolopment and maturation) are carried
out by its metabolite, retinoic acid -.i.e. Vitamin A does not act function
directly rather it acts as a precusor for biologically active retinoids.
Retinoids are powerful regulators of epithelial,
differentiation
and are essential for its maintance.
Click here for more detailed definitions and descriptons of Vitamin
A, retinoids, retinal, retinoic acid etc: Retinoids
and Vitamin
A
For decades high doses of Vitmain A were found to have a positive
effect on keratinising disorders (psorasis, acne etc) but the side effects could not be tolerated. Scientists synthesised
other vitamin A derivatives (retinoids) in an effort to find a drug with
similar or greater therapeutic activity with less toxic side effects.
In 1969, Dr William Bollag of F.Hoffman La Roche, synthesised Accutane
(cis-13-retinoic acid/Isotretinoin) and found a definate clinical response.
According to Orfanos [Br J Dermatol 1980 103 473-81] the risk of side
effects, in particular the teratogenic side effect, were considered too
high to be used to treat such a common compaint as acne.
However the drug subsequently used in clinical trials in USA in the
1970's and approved by the FDA in May 1982 for use in the treatment
of severe recalcitrant cystic acne. The approval came only nine months
after the NDA submission on 523 patients, 160 of which had acne. [See
Dr. Cunnignham presentation (on behalf of Roche) at FDA meetingin 1983]
A review of the NDA submission (obtained via FOI Act) found that patients
were excluded from three of the protocols (including those where the
effect of the drug was examined on patients with keratinisation disorders)
if they had "Neurological function which might be exacerbated by
vitamin-A type toxicity".
Dr Del Vecchio [at the FDA meeting in 1983] described the side effects
of Accutane and said that "just about everything that happens with
Accutane may happen with Vitamin A overdosage". They said that the
only clinical side effects that were known initially were the musocutaneous
and muscoloskeletal side effects.
Accutane/Roaccutane acts to inhibit sebaceous
gland secretions. The current label warnings for Accutane/Roaccutane state
that "the exact mechanism of action of isotretinoin is unknown".
"Retinoic acid (active form of Accutane/Roaccutane) induces differentiation
and reduces proliferation of stem and progenitor cells. It works on
acne by inducing similar events in basel sebocytes. These same actions
also lead to 13-cis-retinoic's side effects, and these are directed
towards proliferating cells in the adult such as in the skin, gut and
bone." Crandall
2004
"A wide ranging effect of retinoic acid is to inhibit proliferation
in dividing cells, and this accounts for its frequent consideration
as an anti-cancer agent."Crandall
2004.
Below is a table of published case reports linking
ingestion of Accutane/Roaccutane to psychiatric adverse events, including
depression and suicide, from 1982 onwards.
See also prospective and retrospective studies discussed
for reports of depression and other psychiatric disorders - Click
here.
See also ADR's for adverse reaction reports reported to the manufacturer,
Roche, and Licensing Authorties - Click
here. |
| Year |
Author |
Psychiatric Adverse Event |
Reference |
Brief Description |
| 2007 |
Sarah J Bailey & Simon Trent, Dept of Pharmacy & Pharmacology, University of Bath, UK. Kally C. O'Reilly & Michelle A Lane from The University of Texas at Austin, TX, USA |
Aggression and Clinical Depression |
"13-Cis-Retinoic Acid Alters Intracellular Serotonin, Increases 5-HT Receptor, and Serotonin Reuptake Transporter Levels In Vitro" Published by Experimental Biology and Medicine |
Using cells cultured in a laboratory, scientists from the University of Bath (UK) and University of Texas at Austin (USA) were able to monitor the effect of the drug (Roaccutane) on the chemistry of the cells that produce serotonin.
They found that the cells significantly increased production of proteins and cell metabolites that are known to reduce the availability of serotonin.
.....“Low levels of serotonin have been linked to depression, as well as bipolar and anxiety disorders. |
| 2006 |
Sarah J Bailey, Dept of Pharmacy & Pharmacology, University of Bath, UK. Kally C O Reilly, Jason Shumake, Gonzalez-Lima & Michelle A Lane from The University of Texas at Austin, TX, USA |
Depression Related behaviour |
"Chronic Administration of 13-Cis-Retinoic Acid Increases Depression-Related Behaviour in Mice" Neuropsychopharmacology (2006) 31, 1919 - 1927 Nature Publishing Group |
A team at Bath University and the University of Texas at Austin investigated the effect of Roaccutane on mice using two tests. Both tests involve putting the mice under stress. In one, they are put in water and forced to swim; in the other, suspended by their tails. Under these circumstances mice will normally swim, climb, or make running movements and thrash around in a bid to escape. But these bouts of activity will be interspersed with periods of immobility, during which the mice appear passive and resigned.
A mouse that is depressed spends longer in the immobile state than one that is healthy. So the team gave adolescent mice Roaccutance in doses that are equivalent to those given to human adolescents, and found that the periods of immobility were significantly increased.
The same tests have been used in the past to test anti-depressants, so are well validated. The conclusion, Dr Bailey said, was that Roaccutane does tend to increase depression-related behaviour in adolescent mice, at levels proportionate to those given to human patients. |
| 2005 |
La Placa M et al |
Acute depression |
La Placa M.
J Eur Acad Dermatol Venereol. 2005 May;19(3):387. Acute depression
from isotretinoin. Another case. |
A 16-year old male teenager, a high school student and
basketball player, was prescribed Isotretinoin. Five weeks later,
the patient appeared to be fretful and began to complain about his
acne, where he had previously showed no embarrassment. His mother
reported an increase in irritability and a loss of concentation at
school. Two weeks later the mother returned to the dermatologist and
said that her son was terribly depressed, often crying and frequently
arguing with his parents.The dermatologist noted that typical features
of major depression were clearly detectable including mood disturbances
and behaviour changes. The treatment was discontinued and mother and
son were advised that psychotic symptoms quickly disappear after discontinuing
the isotretinoin. Unfortunately contact was lost after this episode.
The author noted that "I believe that the number of reports of
acute depression due to isotretinoin therapy are widely underestimated"
and concluded that "it is quite likely that he was probably susceptible
to developing depression, and that his mother;s anxiety had increased
the depressive symptoms". |
| 2005 |
Barak Y et al |
Psychosis on Roaccutane therapy |
Barak Y, Wohl Y, Greenberg Y, Bar Dayan Y, Friedman
T, Shoval G, Knobler HY.Affective psychosis following Accutane (isotretinoin)
treatment.Int Clin Psychopharmacol. 2005 Jan;20(1):39-41. |
Barak reported 10% of soldiers who developed psychosis
while on Roaccutane therapy |
| 2003 |
Van Broekhaven et al |
Completed suicide |
Psychiatric symptoms during Isotretinoin
therapy |
A 22-year old patient with known bipolar
disorder was admitted to psychiatric department for depression and
suicide ideation. He had been given Isotretinoin for ance. During
admission, he committed suicide. The author states that "methodologically
well-performed research is lacking". |
| 2002 |
Robusto et al |
Depression |
Robusto et
al. Acta Med Port. 2002; 15(4):325-6. Depression caused by an anti-acne
agent |
The present clinical case reports an adolescent with
depression, strongly correlated with the adverse reactions of isotretinoin. |
| 2001 |
Ng et al |
Suicide attempt |
Ng CH, Tam MM,
Hook SJ. Acne, Isotretinoin treatment and acute depression. World
J Biol Psychiatry. 2001 Jul;2(3):159-61 |
A 17-year old man with acne vulgaris developed symptoms
of acute depression two weeks after beginning isotretinoin therapy.
The depressive symptoms improved with reduction of dose and treatment
with antidepressants. Dr. Ng however noticed that when isotretinoin
treatment was increased, the depressive symptoms recurred despite
clearing of the skin, leading to an unsuccessful suicide attempt.
Isotretinoin was finally discontinued and the depressive symptoms
resolved |
| 1999 |
Middelkoop et al |
Completed suicide |
Adverse Medication Events:
Roaccutane (Isotretinoin) and the Risk of Suicide: Case Report and
a Review of The Literature and Pharmacovigilance Reports (click here
to download article) |
The article outlines the close relationship between
vitamin A and Roaccutane/Accutane and accordingly similar unwanted
effects to be expected. A review of the literature is documented from
1856 to the present date illustrating these side effects experienced
with Vitamin A intoxication, which include vertigo, headache, irritability,
depression, lethargy, fatigue and Pseudotumor cerebri. It describes
a patient who was treated with Roaccutane and committed suicide. The
author produces evidence to over 1000 reports of psychiatric ADRs
including 47 suicides, 67 suicide attempts and 56 patients with suicide
ideation. This is contrasted with very low numbers for various antibiotics
also used in the treatment of acne. The events surrounding the increased
warnings on Roaccutane in France, the United States, the United Kingdom
and Ireland are documented. Finally caution is recommended for practitioners
to be aware of this life threatening adverse event and that patients
should be thoroughly screened and evaluated for signs of depression
on a frequent and regular basis during therapy. |
| 1998 |
Byrne et al |
Depression (3 patients) |
Byrne A, Costello
M, Greene E, Zibin T. Isotretinoin therapy and depression - evidence
for an association. Ir J Psych Med.1998;15(2)58-60
*Note this publication was submitted for publication on 7 Nov 1996
and accepted on 27 March 1998 |
Three case reports of depression associated with Accutane
therpay are described by psychiatrist, Dr. Alan Byrne. All three cases
had no previous history of depression and no family history of depression
or affective disorders. A gradual improvement of mood was noted in
all patients upon cessation of accutane treatment. Dr Byrne states
" We believe, however, that an association does exist between
depression and the use of isotretinoin for the treatment of acne and
the cases reported here add weight to this belief". |
| 1995 |
Aubin et al |
Suicide attempt |
Aubin S, Lorette G, Muller C, et al Massive isotretinoin
intoxicationClin Exp Dermatol;20(4):348-50 |
Describes massive isotretinoin intoxication in a patient
who took 900 mg (30 times the prescribed dose) in a suicide attempt. |
| 1995 |
Byrne et al |
Depression (3 patients) |
Byrne A. Hnatko G. Depression associated with isotretinoin
therapy [letter]. Canadian Journal of Psychiatry -Revue Canadienne
de Psychiatrie. 40(9):567, 1995 |
A letter descrbing three cases characterized by depression,
anergia, headache, irritability and agitation; two were actively suicidal.
None had previous psychiatric history. |
| 1993 |
Bravard et al |
Suicide attempt, completed suicide and depression (3
patients) |
Isotrétinoíne
et dépression: syons vigilants (Isotretinoin and Depression: Care
is needed) |
This article describes three cases of which depression
is attributed to the ingestion of Roaccutane. It also analyses the
literature on the appearance of depression during treatment with Roaccutane. |
| 1992 |
Duke et al |
Depression |
Duke EE, Guenther L: Psychiatric reactions to the retinoids.
Can J Dermatology 1993; 5:467. |
This article was based on observations of psychiatrists
at Edmonton, Canada who treated two patients for psychiatric disorders
while the patient was taking Roaccutane. The article noted that the
patients had no previous history of depression and also indicated
that the depressive symptoms disappeared when Roaccutane was discontinued.
12. 1993 Nouv Dermatol; 12:215. Bravard P, Krug M, Rzeznick JC: Isotrétinoíne
et dépression: syons vigilants (Isotretinoin and Depression: Care
is needed) This article describes three cases of which depression
is attributed to the ingestion of Roaccutane. It also analyses the
literature on the appearance of depression during treatment with Roaccutane. |
| 1991 |
Gatti et al |
Completed suicide |
Gatti S, Serri F: Acute depression from isotretinoin.
J Am Acad Dermatology 1991; 25:132. |
This article reports the case of a 17-year-old boy who
developed psychiatric problems one month after completing a four-month
course of Isotretinoin. He received psychiatric care but three weeks
later committed suicide.[Also includes Peck answer to letter] |
| 1990 |
Hepburn et al |
Suicide attempt |
Hepburn et al. Deliberate self-poisoning
with isotretinoin. Br J Dermatol; 122, 840-1 |
|
| 1990 |
Scheinman et al |
Depression (7 patients) |
Scheinman PL et al. Acute Depression from Isotretinoin.
JAAD 1990; 22:1112-1114 |
Scheinman et al reported depression in 7 of 700 patients
with cystic acne, psoriasis, cutaneous disorders of keratinization,
or basal cell carcinoma on isotretinoin therapy. The symptoms of depression
resolved within 1 week of stopping therapy. One patient was rechallenged
and symptoms recurred. Two of the seven patients had had previous
Accutane® treatment without episodes of depression. |
| 1989 |
Villalobos et al |
Psychosis |
Duke EE, Guenther L: Psychiatric reactions to the retinoids.
Can J Dermatology 1993; 5:467. |
This is a report on a 16 year old male with acne who
on day 11 of therapy the patient had the onset of hallucinations,
paranoia and impaired speech. This behaviour subsided when drug intake
was stopped, but recurred shortly after resumption of Roaccutane.
8. 1988 Cutis, 42, 399-400 Roytman, M et al Pseudotumor cerebri caused
by isotretinoin Case report of 16-year old girl treated with isotretinoin
at a dosage of 0.7 mg per Kg each day. Side effects included depression,
sever headaches, neurological disorders and impaired night vision. |
| 1986 |
Lindermayr et al |
Suicide
attempt |
Lindermayr et al. Isotretinoin intoxication in attempted
suicide Acta Derm Venereol; 66; 452-3 |
|
| 1982 |
Hazen et al |
Depression
(6 patients) |
Hazen PG et
al. Depression-a side effect of 13-cis-retinoic acid therapy. JAAD1983;
9:278-279. |
Hazen et al reported that 6 of 110 patients with acne
or keratinizing disorders experienced depressive symptoms while being
treated with isotretinoin. One of these patients had a previous history
of depression. Five patients continued on the drug despite the symptoms,
which rapidly resolved upon discontinuation of the isotretinoin. |
| 1982 |
Meyskens et al |
Depression/psychological
changes |
Meyskens, F. L., Jr., Gilmartin, E., Chase,
E., Alberts, D., Surwit, E., Jones, S. E. & Salmon, S. E. (1981).
A broad phase II trial of 13-cis-retinoic acid in advanced cancer.
Paper presented at the Proceedings of the American Association for
Cancer Research, 72nd Annual Meeting, Washington D.C. |
Dr Meyskens observed that in his treatment
of cancer patients with Roacuutan doses of 3 mg/kg/day about 20% developed
psychological changes. He found this observation unusual and did not
attribute the psychological changes to the inability of his patients
to tolerate the side-effects of isotretinoin because these responses
were not seen for other drugs including cytotoxic drugs, which are
ten times worse in terms of toxicity. |
Symptoms
similar to those seen in Accutane® reports (depression, mood swings,
insomnia, fatigue, headache, aggressive behavior, irritability,
and/or uncontrollable crying) have been published for other retinoids
including high dose-vitamin A.
Excessive vitamin A intake results in a toxic syndrome known as hypervitaminosis A.
A publication by Restak in 1972 decribed in detail the development
of a severe toxic psychotic reaction in an 18 year old patient with
no antecedent psychiatric illness[ 1971, Restak]. The patient went
on to develop pseudotumor cerebri. The author states that the case
establishes "vitamin A as an exogenous agent capable of closely
imitating primary psychiatric disease".In 1987 a paper on hypervitaminosis
A syndrome warned of neuropsychiatric symptoms associated with retinoids.
Vitamin
A deficiency has also been shown to produce spatial learning and
memory impairment in rats [Neuroscience. 2002;115(2):475-82] and
excess of retinoic acid can cause learning difficulties [Proc
Natl Acad Sci U S A. 2004 6;101(14):5111-6]
|
13-cis-retinoic
acid is a naturally occuring form of retinoic acid that is normally
present in blood and tissues of humans. 13-cis-retinoic acid is found
in the body upon consumption of Vitamin A, such as liver [Blanar,
2001]. It is understood that the activity of retinoic acid in
specific tissues is controlled by the regulation or its availability,
balancing the rate of retinoic acid synthesis with that of destruction.
The consequences of retinoc acid excess or deficiency can be severe
[Petkovich,
2001]. A study to measure the concentration of retinoids
in the tissues of mice published in 1980 found concentrations of retinoic
acid in the brain of mice [Wang, 1980, Yang, 2005]. |
Several reviews have been published
which discuss retinoid signalling in the adult brain. One of the first
publications suggesting a role of retinoids in the central nervous
system was published in 1994
The function of retinoids (growth, vision, reproduction immune function
etc) are mediated via a retinoid signalling system which include enzymes,
RA receptors and RA binding proteins. In order for retinoic acid to
be present and to have a function in the brain, this sophisticated
molecular machinery must be present. The presence of these retinoid
receptors and proteins have been found in the hippocampus, an area
of the brain associated with memory, learning and emotion.
Retinoic acid exerts its influences at the DNA level where it plays
an important role in regulating transcription of a number of genes. |
Top
|